vobarilizumab

Ligand id: 8363

Name: vobarilizumab

Classification
Compound class Antibody
International Nonproprietary Names
INN number INN
10210 vobarilizumab
Synonyms
ALX-0061
Database Links
Specialist databases
IMGT/mAb-DB 523
Other databases
Search PubMed clinical trials vobarilizumab
Search PubMed titles vobarilizumab
Search PubMed titles/abstracts vobarilizumab
Comments
Vobarilizumab is an investigational bispecific peptide NanobodyTM which binds soluble IL-6R and human albumin (albumin binding being utilised as a half-life extension methodology). Design and production of ALX-0061 is described in patent US8748581 [2]. Vobarilizumab is being developed for the treatment of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Preclinical information is published in [6].
The exact NanobodyTM structure being used as ALX-0061 was not revealed in the covering patent [2], but has been disclosed in the INN submission. Annotated peptide sequences for this therapeutic are available from its IMGT/mAb-DB record.